Cytokinetics, Incorporated
CYTK
Peringkat dalam Saham
#2292
Cytokinetics, Incorporated, a biopharmaceutical company, focuses on... Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM. It also develops Aficamten, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of HCM; and omecamtiv mecarbil, a potential treatment across the continuum of care in heart failure with severely reduced ejection fraction. In addition, the company is involved in developing and Ulacamten, a novel, selective, oral, and small molecule cardiac myosin inhibitor designed to reduce the hypercontractility associated with heart failure with preserved ejection fraction in Phase 1 clinical trials; and CK-089, a fast skeletal muscle troponin activator in Phase 1 clinical trials. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.
Harga Saham
$62.64
Kapitalisasi Pasar
$8.71B
Perubahan (1 hari)
1.12%
Perubahan (1 tahun)
7.19%
Negara
US
Perdagangan Cytokinetics, Incorporated (CYTK)
Kategori
Healthcare
Riwayat dividen untuk Cytokinetics, Incorporated (CYTK)
Saham Cytokinetics, Incorporated (simbol: CYTK) telah membayar total 0 dividen.
Total semua dividen (disesuaikan dengan stock split): 0.00
Imbal hasil dividen (TTM): 0
Total semua dividen (disesuaikan dengan stock split): 0.00
Imbal hasil dividen (TTM): 0
Pembayaran dividen untuk Cytokinetics, Incorporated (CYTK) dari 2026 hingga 2026
Pembayaran dividen tahunan
| Tahun | Dividen (disesuaikan dengan stock split) | Mengubah |
|---|---|---|
| Tidak cukup data untuk tanggal yang disediakan. | ||
Daftar semua pembayaran dividen
| Tahun | Dividen | Mengubah |
|---|---|---|
| Tidak cukup data untuk tanggal yang disediakan. | ||
Pembayaran dividen untuk perusahaan sejenis atau pesaing
| Perusahaan | Jumlah pembayaran dividen | Negara |
|---|---|---|
| 0.00% |
US
|
|
| 0.00% |
US
|
|
| 64.00% |
AU
|
|
| 0.00% |
CH
|
|
| 0.00% |
NL
|